Abstract:
The immune system often recognizes tumour cells and infectious agents from the unique peptides (epitopes) found on their surfaces [1] therefore, synthetic vaccines that combine many epitopes together with appropriate glycal adjuvants that stimulate Cytotoxic T Lymphocytes (CTLs) would have considerable clinical utility.